27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The StrongerMemory program, a structured intervention involving reading aloud, writing by hand, and completing simple math problems, is designed to stimulate the prefrontal cortex and enhance cognitive functioning. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The present study was undertaken to validate the measurement of biomarkers as a supplement to the latest diagnostic criteria for Alzheimer disease (AD) dementia by National Institute on Aging-Alzheimer's Association (NIA-AA) work group using a sample attending a tertiary care center in Southern India. 4 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The early diagnosis of Alzheimer's disease (ADD) has gained new significance through the further discovery of blood biomarkers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Identifying patients at risk for developing mild cognitive impairment (MCI) and Alzheimer disease (AD) remains challenging in clinical practice, even as scientific understanding of dementia advances generally. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study underscores the role of telehealth in increasing AWV uptake and facilitating cognitive assessments. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia risk is influenced by biological and lifestyle factors as well as broader socioeconomic conditions; however, the extent to which socioeconomic deprivation creates structural exposures that affect cognitive aging remains unclear. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results support the hypothesis that engaging in physical activity can compensate for urban-rural differences in cognitive performance in ageing. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of 6,911,104 patients (min=Idaho: 45,160; max=California: 2.46 million), we observed a substantial difference in overall diagnosed prevalence across states of residence: Oregon and Montana had the highest diagnosed prevalence (6.6% and 6.5%, respectively); New Mexico had the lowest (2.3%). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, the pathway to diagnosis (i.e., time from signs/symptoms recognition to diagnosis) ranged from 2 to 15 years. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer Disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β deposition, tau pathology, synaptic dysfunction, neuronal injury and cerebral atrophy. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, a progressive neurodegenerative disorder affecting memory, cognition, and behaviour, poses a major global health challenge in aging populations. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent studies highlight the significance of plasma phosphorylated tau proteins, neurofilament light chain, and amyloid-beta ratios as reliable biomarkers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Wprowadzenie Obniżenie poziomu funkcjonowania poznawczego to częsty problem osób w wieku podeszłym, zwłaszcza kobiet, a jednym z czynników ryzyka jest brak aktywności fizycznej. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to assess the diagnostic contribution of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative dementias presenting with language-predominant symptoms, with or without accompanying behavioral changes, and to evaluate the correspondence between PET-derived metabolic patterns and cerebrospinal fluid (CSF) biomarkers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetric parkinsonism, dystonia, myoclonia) and cortical disorders (apraxia, disorders of complex types of sensitivity, the alien limb phenomenon). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Parameters such as clinical status, GCA scale, MTA scale, Fazekas scale, strategic infarction, Koedam score, stroke, hypertension, diabetes mellitus, dyslipidemia, and cardiovascular disease do not have significant correlations with MoCA-INA scores. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a neurodegenerative disorder affecting millions globally, with early detection being critical for effective management. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's Disease acts as a degenerative brain trauma that results in poor memory, alongside impairing mental functioning. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
While this process allows machine learning models to make more precise and reliable diagnoses, systems developed on the basis of Dr. Roman Poznanski's DOT (Dynamic Optimization of Thought) theory offer a new method in the diagnosis of neurological diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review analyzes current data on the epidemiology, pathogenesis, clinical features, and approaches to the treatment of cognitive impairments in diabetes mellitus (DM). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
However, knowledge alone does not consistently predict screening behavior. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Real-world, administrative claims data is uniquely suited to help characterize the journey of Alzheimer's disease (AD) patients from the onset of disease symptoms through diagnosis and beyond. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The research focuses on the use of biomarkers to diagnose Alzheimer’s disease (AD) in living individuals. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
10 of the 1,775 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →